JJ Meier, B Gallwitz, B Kask, CF Deacon, JJ Holst, WE … - Diabetes, 2004 - Am Diabetes Assoc A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a characteristic of patients
with type 2 diabetes. It was the aim of this study to determine the response of insulin secretion
to different GIP doses administered by intravenous bolus injection and via continuous ... Cited by 41 - Related articles - BL Direct - All 4 versions
JJ Meier, MA Nauck, N Siepmann, M Greulich, JJ Holst, … - Metabolism, 2003 - Elsevier Insulin secretion following the intravenous infusion of gastric inhibitory polypeptide (GIP) is diminished
in patients with type 2 diabetes and at least a subgroup of their first-degree relatives at hyperglycemic
clamp conditions. Therefore, we studied the effects of an intravenous bolus administration ... Cited by 20 - Related articles - All 12 versions
- ►physiology.org JJ Meier, O Goetze, J Anstipp, D … - American Journal of …, 2004 - Am Physiological Soc The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstrated to
inhibit gastric acid secretion and was proposed to possess "enterogastrone" activity. GIP effects
on gastric emptying have not yet been studied. Fifteen healthy male volunteers (23.9 ± ... Cited by 56 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org NN Rudovich, HJ Rochlitz, AFH Pfeiffer - Diabetes, 2004 - Am Diabetes Assoc Our objective was to study whether young first-degree relatives of patients with type 2 diabetes
(FDRs) have altered insulin secretion and insulin clearance in response to gastric inhibitory polypeptide
(GIP) in combination with glucose and arginine. A hyperglycemic clamp (11.1 mmol/l for ... Cited by 29 - Related articles - BL Direct - All 4 versions
- ►endocrinology-journals.org [PDF] A Trumper, K Trumper, D Horsch - Journal of Endocrinology, 2002 - Soc Endocrinology Glucose-dependent insulinotropic polypeptide (GIP) acts as a glucose-dependent growth factor
for -cells. Here we show that GIP and glucose also act synergistically as anti-apoptotic factors
for -cells, using the well- differentiated -cell line, INS-1. Mitogenic and anti-apoptotic ... Cited by 102 - Related articles - BL Direct - All 4 versions
- ►aspetjournals.org N Irwin, BD Green, MH Mooney, B Greer, P Harriott, … - Journal of Pharmacology …, 2005 - ASPET Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone with a potentially
therapeutic role in type 2 diabetes. Rapid degradation by dipeptidylpeptidase IV has prompted
the development of enzyme-resistant N-terminally modified analogs, but renal clearance ... Cited by 22 - Related articles - BL Direct - All 7 versions
SA Hinke, RW Gelling, RA Pederson, S Manhart, C … - Diabetes, 2002 - Am Diabetes Assoc The therapeutic potential of glucose-dependent insulinotropic polypeptide (GIP) for improving
glycemic control has largely gone unstudied. A series of synthetic GIP peptides modified at the
NH 2 -terminus were screened in vitro for resistance to dipeptidyl peptidase IV (DP IV) ... Cited by 57 - Related articles - BL Direct - All 6 versions
- ►endojournals.org T Vilsboll, FK Knop, T Krarup, A Johansen, S … - Journal of Clinical …, 2003 - Endocrine Soc The effect of the insulinotropic incretin hormone, glucagon-like peptide-1 (GLP-1), is preserved
in typical middle-aged, obese, insulin-resistant type 2 diabetic patients, whereas a defective
amplification of the so-called late-phase plasma insulin response (20–120 min) to ... Cited by 78 - Related articles - BL Direct - All 4 versions
JJ Meier, B Gallwitz, M Askenas, K Vollmer, CF Deacon … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1872–1881 DOI 10.1007/s00125-005-1863-7 ARTICLE
JJ Meier . B. Gallwitz . M. Askenas . K. Vollmer . CF Deacon . JJ Holst . WE Schmidt . MA
Nauck Secretion of incretin hormones and the insulinotropic effect ... Cited by 25 - Related articles - BL Direct - All 3 versions
- ►diabetica.co.uk [PDF] N Irwin, VA Gault, BD Green, B Greer, P … - Biological …, 2005 - reference-global.com Fatty acid derivatisation was used to develop two novel, long-acting, N-terminally modified,
glucose-dependent insulinotropic polypeptide (GIP) analogues, N-Ac- GIP(LysPAL16) and
N-AcGIP(LysPAL37). In contrast to GIP, which was rapidly degraded by in vitro incubation ... Cited by 17 - Related articles - BL Direct - All 10 versions
